Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Stanford scientists have developed a new, better binder for the tumor-associated macrophage marker CD206. This binder can be conjugated to a variety of payloads, including an anti-immune checkpoint protein antibody for more selective immune checkpoint blockade.